Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01720147 · ClinicalTrials.gov registry record · Phase 1
Quercetin in Children With Fanconi Anemia; a Pilot Study
A Phase 1 study, sponsored by Children's Hospital Medical Center, Cincinnati.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT01720147 is a Phase 1 study that has completed, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 30 participants.
The verdict
NCT01720147, a Phase 1 study, has completed, sponsored by Children's Hospital Medical Center, Cincinnati.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
Fanconi anemia (FA) is an autosomal recessive disease characterized by progressive bone marrow failure (BMF), congenital abnormalities and a predisposition to malignancy.
Interventions
- DRUG Quercetin (dietary supplement)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2012-07 |
| Est. Completion | 2021-10-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01720147
The ClinicalTrials.gov registry entry for NCT01720147 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Quercetin (dietary supplement) is the first listed.
NCT01720147 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01720147 about?
NCT01720147 is a clinical study titled "Quercetin in Children With Fanconi Anemia; a Pilot Study". Fanconi anemia (FA) is an autosomal recessive disease characterized by progressive bone marrow failure (BMF), congenital abnormalities and a predisposition to malignancy.
What is the current status of trial NCT01720147?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2012-07. Estimated completion is 2021-10-26.
What interventions are being tested in trial NCT01720147?
The interventions under investigation include: Quercetin (dietary supplement) (DRUG).
Who is sponsoring clinical trial NCT01720147?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.